US FDA Brand Name Reviews: Predictability Returns To Process
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration's brand name review process appears to have settled into a more comfortable and predictable part of the new drug review process thanks to recently issued and updated guidance documents for industry on best practices.